Abstract | PURPOSE: METHODS AND MATERIALS: RESULTS: A total of 41 patients were included; 37 had cirrhosis and 38 had measurable tumors. One to four treatments (median, two) were given. The cisplatin dose was 75 mg for the first course and 72 mg for the second. Grade 3-4 (n/n) adverse effects were observed in 14 patients, polymorphonuclear leukocytes (3/0), platelets (5/1), asthenia (1/0), pain (1/0), and vomiting (1/0). Four patients developed pulmonary toxicity; 2 cases were likely related to 131I-Lip administration and 1 was fatal. The response rate was 47% (18 of 38), and the 1- and 2-year survival rate was 73% +/- 7% and 48% +/- 9%, respectively. CONCLUSION: This combination had a tolerable toxicity profile and provided an objective response rate, warranting a phase III trial.
|
Authors | Jean-Luc Raoul, Eveline Boucher, Damien Olivie, Anne Guillygomarc'h, Karim Boudjema, Etienne Garin |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 64
Issue 3
Pg. 745-50
(Mar 01 2006)
ISSN: 0360-3016 [Print] United States |
PMID | 16289908
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Iodized Oil
- Cisplatin
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Hepatocellular
(diagnostic imaging, drug therapy, radiotherapy)
- Cisplatin
(therapeutic use)
- Combined Modality Therapy
- Female
- Humans
- Injections, Intra-Arterial
- Iodized Oil
(therapeutic use)
- Liver Neoplasms
(diagnostic imaging, drug therapy, radiotherapy)
- Male
- Middle Aged
- Radionuclide Imaging
|